Table 1.

Patient Characteristics and Correlates of Virologic Failure.

Variable	Frequency	Virologically Suppressed at 1 Year (n = 77)	Virologic Failure at 1 Year (n = 15)	P Value
Race
White	29	21 (72.4%)	8 (27.6%)	.03
Nonwhite	67	61 (91%)	6 (9%)
Gender
Male	66	53 (80.3%)	13 (19.7%)	.09
Female	34	32 (94%)	2 (6%)
IV drug use (n = 52)
Yes	30	22 (73.3%)	8 (26.7%)	.84
No	22	15 (68.2%)	7 (31.8%)
Smoking (n = 70)
Yes	39	28 (72%)	11 (28%)	.25
No	31	27 (87%)	4 (13%)
Alcohol use (n = 92)
Yes	43	34 (79%)	9 (21%)	.11
No	49	43 (87.7%)	6 (12.3%)
HCV coinfection (n = 76)
Yes	30	22 (73.3%)	8 (26.7%)	.31
No	46	39 (84.8%)	7 (15.2%)
Number of ART pills
1	38	34 (89.5%)	4 (10.5%)	.33
2 or more	62	51 (82.3%)	11 (17.7%)
Duration of ART (n = 99)
More than     1 year	90	76 (84.4%)	14 (15.6%)	.57
Less than     1 year	9	8 (88.8%)	1 (11.2%)
Number of comorbidities
2 or less	74	68 (92%)	6 (8%)	.69
3 or more	26	17 (65.4%)	9 (34.6%)
Number of medications (non-ART)
3 or less	40	33 (82.5%)	7 (17.5%)	.51
4 or more	60	52 (86.6%)	8 (13.4%)

Abbreviations: ART, antiretroviral therapy; HCV, hepatitis C virus; IV, intravenous.

P < 0.05.